# Lethargic Depression Study

> **NCT00064467** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 268 (—)

## Conditions studied

- Epilepsy
- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Extended-release bupropion (HCl)

## Key facts

- **NCT ID:** NCT00064467
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 268 (—)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064467, "Lethargic Depression Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00064467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*